National Cancer Institute National Cancer Institute
U.S. National Institutes of Health National Cancer Institute
NCI Home Cancer Topics Clinical Trials Cancer Statistics Research & Funding News About NCI

Clinical Trial Results

Summaries of Newsworthy Clinical Trial Results

< Back to Main

Page Options
Print This Page  Print This Page
E-Mail This Document  E-Mail This Document
Browse by Cancer Type
Breast Cancer

Lung Cancer

Prostate Cancer

More Results
Search Trial Results

    Search  
Quick Links
Director's Corner

Dictionary of Cancer Terms

NCI Drug Dictionary

Funding Opportunities

NCI Publications

Advisory Boards and Groups

Science Serving People

Español
NCI Highlights
Restructuring the NCI Clinical Trials Enterprise

Clinical Trials Reporting Program

Coordinating Center for Clinical Trials

States Requiring Coverage of Clinical Trial Costs
Related Pages
Prostate Cancer Home Page
NCI's gateway for information about prostate cancer.

Search for Clinical Trials
NCI's PDQ® Cancer Clinical Trials Registry.
Prostate Cancer Trial Results
16.  Surgery Versus Watchful Waiting in Early Prostate Cancer
(Posted: 09/13/2002, Updated: 06/20/2005) - A study published in the May 12, 2005, issue of the New England Journal of Medicine reports that men with localized prostate cancer who underwent radical prostatectomy were less likely to have their cancer spread and less likely to die (from the disease or any cause) than men who were managed by "watchful waiting."

17.  First Evidence That Chemotherapy Extends Life in Advanced Prostate Cancer
(Posted: 06/07/2004, Reviewed: 01/22/2008) - Chemotherapy regimens that include the drug docetaxel extend median survival by two to three months in patients with advanced prostate cancer that is no longer responsive to hormone therapy, two large phase III studies have shown. These are the first clinical trials to show that chemotherapy can improve survival in advanced prostate cancer.

18.  Some Men with Low PSAs Have Prostate Cancer
(Posted: 05/26/2004) - Men with low PSA (prostate specific antigen) levels on screening tests can still have prostate cancer, according to a study released today by scientists from the National Cancer Institute (NCI), part of the National Institutes of Health, and the Southwest Oncology Group, an NCI-funded network of researchers.

19.  Pamidronate Fails to Relieve Bone Complications of Prostate Cancer
(Posted: 01/29/2004) - In a combined analysis of two randomized trials, the drug pamidronate (brand name, Aredia®) failed to relieve bone pain or prevent fractures in men with advanced prostate cancer that had spread to the bones.

20.  Zoledronic Acid Reduces Bone Complications of Advanced Prostate Cancer
(Posted: 06/21/2002, Reviewed: 03/09/2005) - In a study published in the October 2, 2002, issue of the Journal of the National Cancer Institute, patients with prostate cancer that had spread to the bones had fewer fractures and other bone complications when they took a new drug, zoledronic acid (also called zolendronate or Zometa®) than when they took a placebo.
< Previous  1 2 3 4 

A Service of the National Cancer Institute
Department of Health and Human Services National Institutes of Health USA.gov